Loading...
XHKG
2186
Market cap1.45bUSD
Dec 05, Last price  
3.01HKD
1D
-0.99%
1Q
-20.58%
Jan 2017
-34.57%
IPO
-55.01%
Name

Luye Pharma Group Ltd

Chart & Performance

D1W1MN
XHKG:2186 chart
P/E
21.79
P/S
1.70
EPS
0.13
Div Yield, %
Shrs. gr., 5y
3.15%
Rev. gr., 5y
-0.95%
Revenues
6.06b
-1.33%
344,368,000308,294,000508,980,000650,976,000954,750,0001,340,895,0001,774,390,0002,135,943,0002,515,111,0003,154,220,0002,563,129,0002,917,794,0003,814,842,0005,173,385,0006,357,596,0005,539,641,0005,200,226,0005,981,656,0006,143,078,0006,061,441,000
Net income
472m
-11.40%
90,164,00080,912,00058,981,00062,089,000123,547,000136,103,000151,624,000169,032,000310,498,000605,524,000754,523,000891,539,000981,372,0001,303,373,0001,468,562,000706,586,000-144,783,000604,807,000532,605,000471,886,000
CFO
168m
-89.49%
42,872,00051,001,000138,506,000105,903,000163,157,000254,209,000325,018,000152,902,000438,618,000319,096,000394,708,000592,028,000964,102,0001,045,587,0001,744,897,0001,033,449,000182,371,0001,653,796,0001,595,487,000167,764,000
Dividend
Jun 29, 20200.06 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
IPO date
Jul 09, 2014
Employees
5,005
Domiciled in
CN
Incorporated in
BM

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT